Jupiter Asset Management Ltd. Boosts Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Jupiter Asset Management Ltd. increased its holdings in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 10.1% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 1,177,929 shares of the biotechnology company's stock after buying an additional 108,030 shares during the quarter. Jupiter Asset Management Ltd. owned 0.57% of BioCryst Pharmaceuticals worth $8,858,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of BCRX. Geode Capital Management LLC grew its stake in shares of BioCryst Pharmaceuticals by 2.7% in the third quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company's stock worth $36,776,000 after purchasing an additional 127,708 shares during the last quarter. Fisher Asset Management LLC grew its position in shares of BioCryst Pharmaceuticals by 16.9% in the 3rd quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company's stock valued at $25,369,000 after buying an additional 481,359 shares during the last quarter. Two Sigma Advisers LP grew its position in shares of BioCryst Pharmaceuticals by 13.6% in the 3rd quarter. Two Sigma Advisers LP now owns 2,181,012 shares of the biotechnology company's stock valued at $16,576,000 after buying an additional 261,500 shares during the last quarter. FMR LLC increased its stake in shares of BioCryst Pharmaceuticals by 2.4% in the third quarter. FMR LLC now owns 1,988,389 shares of the biotechnology company's stock valued at $15,112,000 after buying an additional 46,110 shares during the period. Finally, Charles Schwab Investment Management Inc. raised its position in shares of BioCryst Pharmaceuticals by 4.9% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,979,992 shares of the biotechnology company's stock worth $14,890,000 after acquiring an additional 91,998 shares during the last quarter. 85.88% of the stock is owned by institutional investors and hedge funds.

Remove Ads

BioCryst Pharmaceuticals Price Performance

Shares of NASDAQ BCRX traded up $0.04 during mid-day trading on Monday, reaching $7.74. 2,759,501 shares of the company's stock traded hands, compared to its average volume of 2,755,519. The business has a 50-day simple moving average of $8.14 and a 200 day simple moving average of $7.85. The stock has a market cap of $1.62 billion, a P/E ratio of -12.69 and a beta of 1.85. BioCryst Pharmaceuticals, Inc. has a 1-year low of $4.03 and a 1-year high of $9.50.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last posted its earnings results on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $131.50 million for the quarter, compared to analysts' expectations of $126.64 million. BioCryst Pharmaceuticals's quarterly revenue was up 40.8% on a year-over-year basis. During the same period last year, the firm posted $0.28 EPS. Equities research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have weighed in on BCRX. Royal Bank of Canada reissued an "outperform" rating and set a $11.00 target price (up previously from $10.00) on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. Wedbush assumed coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They set an "outperform" rating and a $15.00 price objective for the company. HC Wainwright restated a "buy" rating and issued a $30.00 target price on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. JMP Securities reiterated a "market outperform" rating and set a $18.00 price target on shares of BioCryst Pharmaceuticals in a report on Friday, January 31st. Finally, Needham & Company LLC boosted their price objective on BioCryst Pharmaceuticals from $14.00 to $15.00 and gave the company a "buy" rating in a research note on Monday, January 13th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company's stock. According to MarketBeat, BioCryst Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $15.57.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.